Infarmasa’s portfolio consists of over 600 registered products; of which over 500 are currently marketed and has two manufacturing facilities in Lima.
Teva Pharma president and CEO Shlomo Yanai said the acquisition of Infarmasa in Peru expands their activity in Latin America, and highlights their growth strategy for the coming years.
Teva is a pharmaceutical company that develops, produces and markets generic drugs as well as specialty pharmaceuticals and active pharmaceutical ingredients.